Workflow
总市值
icon
Search documents
南京商旅收盘下跌1.15%,滚动市盈率118.79倍,总市值37.49亿元
Sou Hu Cai Jing· 2025-07-29 10:13
Company Overview - Nanjing Commercial Travel Co., Ltd. focuses on commercial trade and tourism, with main products including textiles, machinery, chemical raw materials, metal materials, non-metallic minerals, tourism services, and general retail [1] - As of March 31, 2025, the company had 30,086 shareholders, a decrease of 906 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - For Q1 2025, the company reported revenue of 191 million yuan, a year-on-year decrease of 7.98%, and a net profit of 3.51 million yuan, down 80.03% year-on-year, with a gross profit margin of 22.30% [1] - The current stock price is 12.07 yuan, down 1.15%, with a rolling PE ratio of 118.79 times, and a total market capitalization of 3.749 billion yuan [1] Industry Comparison - The average PE ratio for the trade industry is 47.62 times, with a median of 38.89 times, positioning Nanjing Commercial Travel at the 33rd rank within the industry [1][2] - The industry average market capitalization is 9.521 billion yuan, while the median is 7.918 billion yuan [2]
可孚医疗收盘上涨1.01%,滚动市盈率25.63倍,总市值77.41亿元
Sou Hu Cai Jing· 2025-07-29 09:56
Core Viewpoint - Cofoe Medical's stock closed at 37.02 yuan, with a rolling PE ratio of 25.63 times, and a total market value of 7.741 billion yuan, indicating a relatively lower valuation compared to the industry average [1][2]. Company Overview - Cofoe Medical specializes in the research, production, sales, and service of medical devices, with a diverse product range including blood glucose systems, blood pressure monitors, and various medical consumables [2]. - The company has received several accolades, including recognition as a potential brand in the Chinese retail pharmaceutical market for 2023-2024 and being listed among the key trademark protection catalog in Changsha [2]. Financial Performance - In the first quarter of 2025, Cofoe Medical reported revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.425 million yuan, down 9.68%, with a gross profit margin of 52.17% [2]. Industry Comparison - The average PE ratio for the medical device industry is 55.46 times, with a median of 37.74 times, positioning Cofoe Medical at the 51st rank within the industry [1][3]. - Cofoe Medical's PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [3].
中电港收盘上涨1.91%,滚动市盈率58.60倍,总市值158.44亿元
Jin Rong Jie· 2025-07-29 09:29
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhongdian Port, with a closing price of 20.85 yuan and a PE ratio of 58.60 times, indicating a strong market position within the trade industry [1][2] - Zhongdian Port's total market capitalization is reported at 15.844 billion yuan, ranking 28th in the trade industry based on PE ratio, which has an average of 47.62 times and a median of 38.89 times [1][2] - The company experienced a net outflow of main funds amounting to 2.6682 million yuan on July 29, with a total outflow of 35.3139 million yuan over the past five days, indicating a trend of capital withdrawal [1] Group 2 - Zhongdian Port's main business includes electronic component distribution, design chain services, supply chain collaboration, and industrial data services, with key products being memory, processors, analog devices, and RF/wireless connections [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating revenue of 17.470 billion yuan, representing a year-on-year increase of 49.01%, and a net profit of 84.5551 million yuan, up 64.99% year-on-year, with a gross profit margin of 2.66% [1]
乐普医疗收盘上涨1.10%,滚动市盈率204.42倍,总市值293.56亿元
Sou Hu Cai Jing· 2025-07-29 09:12
来源:金融界 乐普(北京)医疗器械股份有限公司的主营业务是医疗器械、药品、医疗服务及健康管理。公司的主要产 品是医疗器械、药品、医疗服务及健康管理。 最新一期业绩显示,2025年一季报,公司实现营业收入17.36亿元,同比-9.67%;净利润3.79亿元,同 比-21.44%,销售毛利率64.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13乐普医疗204.42118.881.91293.56亿行业平均 55.4650.344.76115.47亿行业中值37.7437.642.7056.85亿1九安医疗10.9411.070.86184.69亿2英科医疗 13.3414.381.19210.74亿3新华医疗15.3914.261.2598.65亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2816.331.87154.02亿6奥美医疗16.3015.971.6858.89亿7康德莱17.0517.061.4136.73亿8九强生物 17.6216.382.1687.24亿9奥泰生物18.0719.051.4657.63亿10维力医疗18.5919.332.1842.4 ...
开立医疗收盘下跌1.05%,滚动市盈率276.08倍,总市值138.81亿元
Sou Hu Cai Jing· 2025-07-28 09:48
Core Viewpoint - The company, Kaili Medical, is experiencing a decline in stock price and profitability, with a high PE ratio compared to industry averages, indicating potential overvaluation in the medical device sector [1][2]. Company Overview - Kaili Medical specializes in the research, development, production, and sales of medical diagnostic and treatment equipment, including ultrasound diagnostic devices, endoscopes, minimally invasive surgical products, and cardiovascular intervention products [1]. - The company has over 20 years of experience in the ultrasound industry and is recognized as a high-tech enterprise, having developed core technologies for color Doppler ultrasound machines and probes [1]. - Kaili Medical holds the second-largest market share among domestic manufacturers in China and ranks tenth globally in the ultrasound market, showcasing strong brand influence and competitiveness [1]. Financial Performance - For the first quarter of 2025, Kaili Medical reported revenue of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit of 8.07 million yuan, down 91.94% compared to the previous year [1]. - The company's gross profit margin stands at 63.19% [1]. Market Position - As of July 28, 2023, Kaili Medical's stock closed at 32.08 yuan, with a rolling PE ratio of 276.08, significantly higher than the industry average of 55.28 and the median of 38.06 [1][2]. - The total market capitalization of Kaili Medical is 13.881 billion yuan [1][2]. - There are 32 institutional investors holding shares in Kaili Medical, with a total holding of 24.7034 million shares valued at 734 million yuan [1].
理邦仪器收盘上涨1.71%,滚动市盈率40.22倍,总市值75.88亿元
Sou Hu Cai Jing· 2025-07-28 09:13
Core Insights - The company, Lifesense Medical, closed at 13.09 yuan on July 28, with a 1.71% increase, and a rolling PE ratio of 40.22, marking a new low in 104 days, with a total market capitalization of 7.588 billion yuan [1][2] - The average PE ratio in the medical device industry is 55.28, with a median of 38.06, placing Lifesense Medical at the 79th position in the industry ranking [1][2] - As of the first quarter of 2025, four institutions held shares in Lifesense Medical, with a total of 55,200 shares valued at 0.01 million yuan [1] Company Overview - Lifesense Medical specializes in the research, development, production, sales, and service of medical electronic devices and in vitro diagnostic products [1] - Key products include critical care monitoring solutions, bedside monitoring solutions, intelligent vital signs management solutions, various ECG systems, ultrasound diagnostic systems, perinatal monitoring solutions, gynecological diagnostic solutions, blood gas analyzers, and molecular diagnostic products [1] Financial Performance - For the first quarter of 2025, the company reported revenue of 420 million yuan, a year-on-year decrease of 5.25%, while net profit was 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [2] - The sales gross margin stood at 58.34% [2]
东富龙收盘下跌1.26%,滚动市盈率72.05倍,总市值107.75亿元
Sou Hu Cai Jing· 2025-07-28 09:13
Group 1 - The core business of the company is to provide pharmaceutical companies worldwide with pharmaceutical processes, core equipment, and overall system engineering solutions [1] - The company's main products include bioprocessing, formulation, engineering solutions, and food equipment engineering [1] - As of the first quarter of 2025, the company reported revenue of 1.137 billion yuan, a year-on-year increase of 2.58%, and a net profit of 20.1326 million yuan, a year-on-year decrease of 68.87% [1] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 72.05, significantly higher than the industry average of 55.28 and the industry median of 38.06 [2] - The total market capitalization of the company is 10.775 billion yuan [2] - As of the first quarter of 2025, there is only one institutional holder of the company, with a total holding of 2.1845 million shares valued at 2.9 million yuan [1]
超研股份收盘上涨1.95%,滚动市盈率73.53倍,总市值116.38亿元
Sou Hu Cai Jing· 2025-07-25 10:14
Company Overview - Chao Yan Co., Ltd. closed at 27.17 yuan, up 1.95%, with a rolling PE ratio of 73.53, marking a new low in 14 days, and a total market value of 11.638 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 55.41 and a median of 37.94, placing Chao Yan at the 96th position in the industry ranking [1] - As of the first quarter of 2025, 118 institutions held shares in Chao Yan, with a total holding of 71,100 shares valued at 0.02 billion yuan [1] Business Operations - Chao Yan specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [1] - The main products include industrial ultrasound, medical ultrasound, X-ray, and related accessories [1] - The company has established a strong market presence and stable customer base, with its industrial ultrasound non-destructive testing products recognized as a Guangdong Province brand [1] - In 2022, the company received a second-class National Defense Technology Invention Award from the Ministry of Industry and Information Technology for its project on "New Technology for High-Precision Non-Destructive Testing of Complex Large Components and Its Major Applications" [1] Financial Performance - In the first quarter of 2025, Chao Yan reported operating revenue of 98.4324 million yuan, a year-on-year increase of 28.69% [1] - The net profit for the same period was 39.3220 million yuan, reflecting a year-on-year growth of 47.70% [1] - The sales gross margin stood at 73.83% [1]
英科医疗收盘上涨3.40%,滚动市盈率12.99倍,总市值205.18亿元
Sou Hu Cai Jing· 2025-07-25 09:45
Core Viewpoint - The company Inco Medical has shown a significant increase in stock price and profitability, but it is experiencing a net outflow of funds, indicating potential investor concerns despite strong financial performance [1][2]. Company Summary - Inco Medical's stock closed at 31.34 yuan, up 3.40%, with a rolling PE ratio of 12.99 times and a total market capitalization of 20.518 billion yuan [1]. - The company specializes in the research, production, and sales of high-performance personal protective products, including disposable nitrile gloves, PVC gloves, isolation gowns, masks, and various medical equipment [1]. - For Q1 2025, Inco Medical reported revenue of 2.494 billion yuan, a year-on-year increase of 13.20%, and a net profit of 353 million yuan, reflecting a year-on-year growth of 48.08% with a gross profit margin of 24.16% [1]. Industry Summary - The average PE ratio for the medical device industry is 55.41 times, with a median of 37.94 times, positioning Inco Medical at the 32nd rank within the industry [1][2]. - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [2].
开立医疗收盘上涨1.82%,滚动市盈率279.00倍,总市值140.29亿元
Sou Hu Cai Jing· 2025-07-25 09:45
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kaili Medical, indicating a significant decline in revenue and profit in the latest quarter [1][2] - As of July 25, Kaili Medical's stock closed at 32.42 yuan, with a PE ratio of 279.00, marking a new low in 32 days, and a total market capitalization of 14.029 billion yuan [1] - The average PE ratio for the medical device industry is 55.41, with a median of 37.94, positioning Kaili Medical at 118th in the industry ranking [1][2] Group 2 - In the first quarter of 2025, the company reported an operating income of 430 million yuan, a year-on-year decrease of 10.29%, and a net profit of 8.0746 million yuan, down 91.94% [2] - The company's gross profit margin stands at 63.19%, indicating a relatively high profitability despite the decline in revenue and net profit [2] - Kaili Medical specializes in the research, development, production, and sales of medical diagnostic and treatment equipment, with a strong presence in the ultrasound industry and a market share ranking second among domestic manufacturers and tenth globally [1]